上(shang)海(hai)二(er)本(ben)大(da)學(xue)歐洲國家飲(yin)食(shi)菌加工(gong)(gong)(gong)工(gong)(gong)(gong)藝新(xin)技(ji)術研發管理(li)(li)專(zhuan)業(ye)課(ke)程產業(ye)帶(dai)適用(yong)(yong)氧嗪酸鉀成(cheng)立SD大(da)鼠呼吸功(gong)能(neng)衰竭高(gao)血(xue)(xue)血(xue)(xue)尿(niao)(niao)酸偏高(gao)血(xue)(xue)癥(zheng)模型工(gong)(gong)(gong)具(ju)，切合線上(shang)藥(yao)理(li)(li)學(xue)學(xue)和分子式對接的，鉆研梔子-茯苓提煉物(wu)(wu)解決高(gao)血(xue)(xue)血(xue)(xue)尿(niao)(niao)酸偏高(gao)血(xue)(xue)癥(zheng)大(da)鼠血(xue)(xue)血(xue)(xue)尿(niao)(niao)酸偏高(gao)功(gong)能(neng)還有其適用(yong)(yong)。該(gai)優(you)秀(xiu)成(cheng)果在上(shang)海(hai)省(sheng)大(da)的愛心公益建(jian)設工(gong)(gong)(gong)程和上(shang)海(hai)省(sheng)精準(zhun)扶(fu)貧膳食(shi)纖維(wei)與衛(wei)生食(shi)品加工(gong)(gong)(gong)創新(xin)技(ji)術引智(zhi)產業(ye)帶(dai)等建(jian)設工(gong)(gong)(gong)程支持系統下，以“Inflammatory Response and Oxidative Stress as Mechanism of Reducing Hyperuricemia of Gardenia jasminoides-Poria cocos with Network Pharmacology”為題，發表過在中科(ke)院研究所二(er)區刊(kan)物(wu)(wu)Oxidative Medicine and Cellular Longevity（IF 6.543）。

      網(wang)藥(yao)學(xue)學(xue)效果(guo)(guo)屏幕上顯示，特(te)征分離(li)(li)出來(lai)TCMSP的(de)(de)梔(zhi)子-茯苓分離(li)(li)出來(lai)物(wu)的(de)(de)30個有用化學(xue)物(wu)質和(he)183個內在靶點(dian)，經選(xuan)擇收(shou)獲(huo)與(yu)(yu)HUA消化道(dao)疾(ji)病遭(zao)受(shou)、進展關于的(de)(de)靶點(dian)639個，建設方(fang)案(an)韋恩(en)圖的(de)(de)梔(zhi)子-茯苓分離(li)(li)出來(lai)物(wu)根治(zhi)HUA的(de)(de)內在靶點(dian)40個，GO效果(guo)(guo)具體(ti)(ti)(ti)探討核(he)心收(shou)錄防氧化應(ying)激性反(fan)應(ying)等生理學(xue)學(xue)過(guo)程中，血(xue)組(zu)(zu)織(zhi)消亡，血(xue)組(zu)(zu)織(zhi)要素腎上腺(xian)素受(shou)體(ti)(ti)(ti)等酶(mei)活性酶(mei)類地(di)方(fang)碳(tan)原子效果(guo)(guo)業內，與(yu)(yu)線(xian)粒(li)身體(ti)(ti)(ti)膜(mo)等血(xue)組(zu)(zu)織(zhi)形(xing)成業內；KEGG通(tong)(tong)道(dao)生物(wu)富集(ji)具體(ti)(ti)(ti)探討核(he)心收(shou)錄TNF電(dian)磁(ci)波(bo)通(tong)(tong)道(dao)(TNF signaling pathway)、IL-7電(dian)磁(ci)波(bo)通(tong)(tong)道(dao)（IL-7signaling pathway）等支原體(ti)(ti)(ti)感(gan)染(ran)通(tong)(tong)道(dao)途(tu)。

     ; Figure 2. PPI protein interaction network of GPE in treatment of HUA targets (A) and Cytonca Core Network Analysis (B, C)

      Figure 2. PPI protein interaction network of GPE in treatment of HUA targets (A) and Cytonca Core Network Analysis (B, C)

      爬行動物實驗結果(guo)提(ti)(ti)示，與建模組(zu)相較于，梔子-茯苓領取物可(ke)差異(yi)性(xing)性(xing)減(jian)(jian)少(shao)高(gao)(gao)血(xue)(xue)尿(niao)酸(suan)高(gao)(gao)血(xue)(xue)癥(zheng)大(da)鼠血(xue)(xue)漿中(zhong)(zhong)(zhong)的血(xue)(xue)尿(niao)酸(suan)高(gao)(gao)濃度(du)；各用藥(yao)量組(zu)可(ke)差異(yi)性(xing)性(xing)提(ti)(ti)升血(xue)(xue)漿和(he)腎臟器官組(zu)識中(zhong)(zhong)(zhong)SOD、CAT、GSH-Px抗逆性(xing)和(he)T-AOC關卡(ka)，減(jian)(jian)少(shao)血(xue)(xue)漿中(zhong)(zhong)(zhong)ROS、MDA、NADPH關卡(ka)；高(gao)(gao)用藥(yao)量組(zu)可(ke)差異(yi)性(xing)性(xing)減(jian)(jian)少(shao)血(xue)(xue)漿中(zhong)(zhong)(zhong)車用尿(niao)素(su)氮、肌酐、β2-MG的濃度(du)。

      Figure 4. Effect of GPE on the levels of CAT(A), GSH-PX(B), MDA(C), NADPH(D), ROS(E), SOD(F), and T-AOC(G) in hyperuricemic rats. Compared with BC, * P < 0.05, ** P < 0.01, *** P < 0.001; Compared with MC, # P < 0.05, ## P < 0.01, ### P < 0.001.

      Figure 5. Effects of GPE on BUN(A), CRE(B), β2-MG(C), and XOD(D) levels in hyperuricemic rats. Compared with BC, * P < 0.05, ** P < 0.01, *** P < 0.001; Compared with MC, # P < 0.05, ## P < 0.01, ### P < 0.001.

      整合往上結論，梔子(zi)-茯苓(ling)水(shui)提物醫療(liao)HUA包括多組成、多靶點(dian)、多徑路總布局(ju)的(de)調(diao)節的(de)的(de)功效基本特征，經兩(liang)棲動物研(yan)究查(cha)證梔子(zi)-茯苓(ling)添加物能(neng)相(xiang)關(guan)(guan)系數(shu)削(xue)減(jian)氧嗪酸(suan)(suan)鉀分(fen)析的(de)高血(xue)(xue)血(xue)(xue)尿酸(suan)(suan)血(xue)(xue)癥大鼠血(xue)(xue)血(xue)(xue)尿酸(suan)(suan)平行，改善腐蝕應激發(fa)(fa)(fa)應會產生(sheng)的(de)發(fa)(fa)(fa)炎發(fa)(fa)(fa)應與(yu)脾(pi)腎技能(neng)磨損。其的(de)功效已經與(yu)調(diao)節作(zuo)用(yong)TNF數(shu)據(ju)信(xin)息(xi)徑路(TNF signaling pathway)、IL-7數(shu)據(ju)信(xin)息(xi)徑路（IL-7signaling pathway）等(deng)發(fa)(fa)(fa)炎數(shu)據(ju)信(xin)息(xi)徑路呈現(xian)相(xiang)關(guan)(guan)。

      在以上基礎研究理論支持下，河南中大恒源生物科技股份有限公司進行了應用轉化，注冊了中大薈萃品牌商標，并制定了企業標準，獲得了生產許可，產品即將上市銷售。
     
      (文章來源：食品科學雜志)